Several studies on HDAC inhibitors have confirmed that, in AR and CRS, it can restore the nasal epithelial physical and chemical barrier, involving promoting TJ protein expression and reorganizing the TJ network. Here, HDAC9 is linked to congenital rubella syndrome.